array

Company

Hudson Alpha

In diligent pursuit of our goal to advance array-based technologies for biological research, detection and diagnostics, MI creates array products which generate the highest quality microarray data. MI innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000. MI has been privately held since May 2010.

In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.


Contact MI

MI values your inquiries and orders. Our personnel are available from 8:00 am - 6:00 pm Central Time to assist you. If you do not receive a reply or order confirmation within 24 hours, please resend your message.

MI - Microarrays Inc.
601 Genome Way
Huntsville, AL 35806
P: 256-327-0544
F: 256-327-0981
info {AT} microarrays {DOT} com

Please complete the Contact MI form. An MI scientist will contact you with information about how MI can accelerate your research efforts.

Directions to the MI Facility


View Larger Map

Distributors

Distributors for MI Products and Services

United Kingdom and Eire

Cambio LtdCambio
1 The Irwin Centre
Scotland Road
Dry Drayton Cambridge
CB23 8AR, UK

Tel. +44 (0) 1954 210200
Fax. +44 (0) 1954 210300
www.cambio.co.uk
support@cambio.co.uk

France

CliniSciencesCliniSciences
183, avenue Georges Clémenceau
92000 Nanterre
FRANCE

Tel. +33 (0)9 77 40 09 09
Fax. +33 (0)9 77 40 10 11
www.clinisciences.com
info@clinisciences.com

Germany, Austria and Switzerland

BioCat GmbHBioCat
Technologiepark Heidelberg
Im Neuenheimer Feld 584
D-69120 Heidelberg, DE

Tel. +49 (0) 6221 7141516
Fax. +49 (0) 6221 7141529
www.biocat.com
info@biocat.com

Greece, Cyprus and the Balkans

BIOSOLUTIONS LtdBiosolutions
249 Mesogion Ave.,
15451 N. Psychiko,
Athens, Greece

Tel. +30 (0) 210 6753453
Fax. +30 (0) 210 6753454
www.biosolutions.gr
info@biosolutions.gr

Netherlands, Belgium, Luxembourg, and Spain

Isogen Life Science B.V. Isogen Life Science B.V.
3454 PW De Meem,
The Netherlands

Tel. +31 (0) 30 688 0771
Fax. +31 (0) 30 688 8009
www.isogen-lifescience.com
info@isogen-lifescience.com

Norway, Sweden, Finland, Denmark, and Estonia

Immuno Diagnostic Oy Immuno Diagnostic Oy
Kaivokatu 16,
13100 Hameenlinna,
Finland

Tel. +358 3 615 370
Fax. +358 3 682 2039
http://www.immunodiagnostic.fi/portal/fi/
info@immunodiagnostic.fl

Poland

Syngen Biotech Syngen
ul. Ostródzka 13,
54-116 Wrocław

Tel. +48 71 349-70-13
Fax. +48 71 349-70-33
http://www.syngen.pl
info@syngen.pl

Japan

Cosmo Bio Co. Ltd. Cosmo Bio CO., Ltd.
Toyo-Ekimae Bldg., 2-20
Toyo 2-Chome
Koto-ku, Tokyo 135-0016

Tel. +03 5632 9610 / 9620
Fax. +358 3 682 2039
www.cosmobio.co.jp
mail@cosmobio.co.jp

MI News

DEMAND FOR GENE EXPRESSION SERVICES NOW MET BY NEW SERVICE LABS AT MICROARRAYS INC

MI offers both standard and highly customized microarray laboratory services for a large variety of human, animal, plant and micro organisms

March 22, 2012 Huntsville, AL (PRWEB) MI has parlayed their extensive expertise in all aspects of gene expression science to meet the demand for custom laboratory services for both large and small gene expression projects. Available across a range of diagnostic, drug development and life sciences applications, the MI Services Lab offers the widest availability of microarrays for human and model systems, including rat and mouse.

Immediately available, the newly expanded services labs handle a variety of microarray platforms to meet researchers needs including arrays from Affymetrix, Illumina, and others. MI’s own highly sensitive MI ReadyArrays™ and MI PathArrays™ are available as standard products or in highly customized formats for services projects too, allowing for a combination of whole genome or targeted gene expression profiles that include specific biomarkers for a client’s particular areas of interest.

Announcing the launch of these new services, Joel Peek, President and CEO of MI stated, "The customized laboratory services that we've provided on a select project basis will now be made available to everyone. Regardless of the size of their project, our services facility will enable researchers to take full advantage of the extensive microarray expertise that MI has developed over the past 12 years. We're excited by this new offering and look forward to assisting researchers with their array projects."

About MI

MI is an emerging leader in molecular diagnostics and analysis of DNA and proteins. MI's innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Diatherix Laboratories and Microarrays Inc. form Strategic Partnership

New alliance to bring more sensitive and accurate clinical tests into physicians' arsenal for detecting infectious diseasesl

March 22, 2012 Huntsville, AL (PRWEB) Diatherix Laboratories and Microarrays Inc. (MI) jointly announce they have entered a strategic partnership to develop industry leading infectious disease diagnostic assays.

The ever-increasing prevalence of infectious and drug-resistant organisms requires that diagnostic platforms be highly adaptable and progressively more comprehensive.

With this partnership the companies will integrate their proprietary technologies to develop and continually update diagnostic assays, which will achieve the maximum flexibility necessary to better serve the healthcare community.

"This collaboration brings together all of the necessary modalities of discovery, development and implementation for dynamic state of the art diagnostic assays," said Joel Peek, Ph.D., MI's chief executive officer. Diatherix's chief executive officer, Dennis Grimaud, added that "the combination of Diatherix's unique diagnostic identification technology combined with MI's extremely sensitive detection platform will not only assist physicians in accurate testing results for infectious disease, but will also assist in lowering the overall cost of diagnostic testing".

About Diatherix

Diatherix Laboratories, Inc. is a CLIA certified high complexity reference laboratory providing infectious disease diagnostics. Diatherix's innovative testing technology can diagnose a wide variety of infectious diseases faster and more accurately than traditional testing. Their unique analysis platform has been proven to result in better patient outcomes and significant hospital savings.

About MI

MI is an emerging leader in molecular diagnostics and analysis of DNA and proteins. MI's innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Newly Independent, Microarrays Inc. Sets Sights on Molecular Diagnostics Market

October 11, 2011 (BioArray NEWS, by Justine Petrone) Microarrays Inc. Microarrays Inc. will later this month launch focused microarrays for studying gene pathways related to growth factors, inflammation, and apoptosis. The pending launch is part of a larger decision by the Huntsville, Ala.-based firm to expand beyond selling whole-genome arrays to offering a menu of catalog focused chips.

CEO Joel Peek said that MI could ultimately offer between 20 and 25 such arrays, which it calls PathArrays. Next quarter, for instance, the firm will begin selling arrays for studying transcription factors, cancer, and protein kinases.

"Our goal is to release three additional pathway-specific arrays every quarter," said Peek. He said that the selection of each research-specific area is being driven by interactions between MI and researchers. "Presently, our third pathway-specific selection is near finalization and we've begun evaluating the fourth-wave candidates," Peek said. "However, we anticipate flux in the selection process as word gets out about the tools line and we hear from more interested researchers."Read more >>

Microarrays Inc Introduces MI PathArray Assays for Apoptosis, Growth Factors, and Inflammation

Specific Research Interests are the Focus of New Discovery Tool

HUNTSVILLE, AL, October 19, 2011 (PRWEB) Microarrays Inc (MI) launches its new MI PathArray assays for studying targeted biological pathways. These pathway-centric arrays provide the highest microarray sensitivity in the form of more sharply focused research-specialty arrays, in a multi-assay format. The MI PathArray assays bring a fresh research tool to laboratories involved in the exploration of biological pathways.

MI PathArray assays are ready for immediate shipment for three popular areas of research: Apoptosis, Growth Factors, and Inflammation. MI will quickly expand the MI PathArray products by launching multiple new arrays each quarter. Once complete the MI PathArray product line will include arrays, kits, and hardware for sample preparation, processing, and array hybridization.

Joining the trend toward interactive research development among research tool developers and scientists, MI has initiated a social media campaign using Facebook. Researchers are invited to list their suggestions for upcoming MI PathArray assay development, the evolution of current MI PathArray content and also to participate as a beta testing laboratory.

During the announcement of the release of the new MI PathArray product, company President Joel Peek commented, “MI PathArray assays enable researchers to rapidly spotlight the pertinent targets of their chosen system. With focused and simplified analysis, in conjunction with a multi-assay format, these arrays will help to speed discovery while reducing costs and sample usage. MI has designed these products to strike the right balance between overall target content, cost per assay, and ease of use when compared to traditional whole genome arrays or some of the qPCR formats which can be lacking in content. Moreover, the content of these arrays will be continually updated with the latest research discoveries to remain cutting-edge tools to enable further discoveries.“

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

Three New Agreements in the European Union Expand Business Opportunities for Microarrays Inc

EU Distributors Now Offer Unique Microarray Inc Capabilities Which Allow the Creation of Research Tools and Diagnostic Tests to Screen for Biological Agents and Other Molecules

HUNTSVILLE, AL, June 9, 2011 (PRWEB) Microarrays Inc (MI) announces distribution agreements, which will facilitate expansion of MI’s commercial activities into the European Union biotechnology markets. Three distributors, Cambio Ltd (UK and Eire; cambio.com), BioCat GmbH (Germany, Austria, and Switzerland; biocat.com), and Biosolutions Ltd. (Greece, Cyprus, and the Balkans; biosolutions.com) will serve as exclusive distributors for MI products and services, including MI’s custom arrays for biological research, detection and diagnostics markets.

Andrew Jennings, President of Business Development stated, "This is an exciting new chapter in our development, we are thrilled to have such high caliber partners representing us in these markets. I believe their knowledge of the local biotechnology landscape coupled to a commitment to excellence will drive our growth in Europe and provide our customers the highest level of service."

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

MI Appoints New President of Business Development to Expand Array Markets Including the Rapidly Developing High-Throughput Arrayed Screening and Diagnostics Sectors

New Microarrays Inc. President of Business Development Andrew Jennings Sees Boundless Growth Opportunities for the Company in Increasing Demand for MI Proprietary Technology Which Enables Moving Traditional Microtiter Plate Assays to High Efficiency Arrays

HUNTSVILLE, AL, February 7, 2011 (PRWEB) Microarrays Inc (MI) today announced the appointment of Andrew Jennings as President of Business Development to lead the expansion of MI's commercial activities. With more than 20 years developing strong sales, marketing and business development organizations for technology companies, Andrew lead the sales organization for Open Biosystems (now Thermo Fisher Scientific) for the last five years. During this time, he spearheaded innovative commercial initiatives to partner with customer organizations, growing significantly ahead of the general biotechnology market and much larger competitors.

"I believe MI's proprietary array techniques and game-changing approach to the manufacture and development of microarray technology empowers our customers to better serve the biological research, detection and diagnostics markets," said Andrew Jennings. "Our early partnerships have allowed MI to mature its products and services, and we will build on this to serve more customers and market segments. I'm excited to be a part of the MI team leading the field in the rapidly developing field of arrayed screening."

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

New MI - Microarrays Inc. Website Showcases Advanced Microarray Capabilities for Research and Diagnostic Assay Applications

Microarrays Inc. Launches Its Newly Designed Website at http://www.microarrays.com Providing a Comprehensive Overview of Their Cutting-Edge Manufacturing Services for Array- based Research and Diagnostic Tools.

HUNTSVILLE, AL, January 20, 2011 (PRWEB) MI, also known as Microarrays Inc, has launched its newly designed website, at http://www.microarrays.com.
The dramatically redesigned site provides potential clients with a comprehensive overview of the cutting-edge manufacturing services for array-based research and diagnostic tools offered by MI.

MI capabilities in the proteomics, assay development and diagnostic markets are prominently featured reflecting the growing demand for new tools for the exciting areas of clinical investigation and research. The new website offers information on refinements to the established MI ReadyArrays for assessing gene expression. Researchers will find detailed information for each of the 40+ organisms offered.

Echoing the excitement of all those involved in the new website's design and construction, Joel Peek, MI President and CEO, commented, "The new web site illustrates many of the capabilities that MI has provided to the research and commercial communities for over a decade now. It provides an enhanced snapshot of the experience and expertise we've developed as a large- scale manufacturing partner and reflects our abilities to respond to client needs, whether they are in the area of product development or diagnostics or healthcare, etc. We're excited to showcase our abilities and look forward to new dialogs and challenges."

About MI

MI's corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

Newly Independent, Microarrays Inc. Sets Sights on Molecular Diagnostics Market

JULY 20, 2010 (BioArray NEWS, by Justine Petrone) The management Of Microarrays Inc. this week announced that it has purchased the firm from Vanderbilt University, which had owned the company since it founded MI 10 years ago.

The company's managers worked with a group of independent investors to purchase the firm, but did not name the new investors or disclose the sum paid to acquire the company.

According to CEO Joel Peek, MI's change in ownership reflects a shift in its business plans. While it has served as an array foundry for research and diagnostic customers for a decade, it is now seeking to apply its expertise in assay design to the clinical market. Read more >>

Investors buy Vandy biotech Microarrays Inc., set up shop in Huntsville

JULY 19, 2010 (NASHVILLE BUSINESS JOURNAL, by Dan Hieb) - Vanderbilt University has sold a genetic research tool to private investors who intend to speed its development and make its technology available to biotech companies.

Terms of the deal were not disclosed, but Microarrays Inc. CEO Joel Peek said it does not involve any licensing payments to Vanderbilt.

Microarrays Inc. has functioned as its own company since 2000 but moved to Huntsville, Ala., in 2008 to become part of the HudsonAlpha Institute for Biotechnology, a nonprofit research institute that is part of a 150-acre biotech research park. Peek said the research park has provided the company with opportunities to collaborate with like-minded researchers and other new biotechs such as iCubate and Conversant Healthcare Systems.

Economic developers and other leaders in Middle Tennessee have been preaching for years in an orchestrated effort to lure fast-growing biotechnology companies and their high-paying jobs, but the area offers nothing comparable to the 260,000-square-foot facility that was singled out for praise last July by R&D Magazine.

Microarray's technology grew out of techniques developed by the Vanderbilt-Ingram Comprehensive Cancer Center. Researchers developed a way to "print" biological material — called capture probes — onto surfaces such as glass slides. The biological samples can be anything from snippets of genetic material to proteins to other organic compounds. The capture probes are designed to react with the genetic sample being studied, providing a road map that can help detect specific diseases of abnormalities.

As an example, Peek described a future in which a clinician could take a sample from a patient suffering from an upper respiratory illness, use a microarray designed to detect common pathogens, then treat the patient based on the specific disease detected.

"Vanderbilt University has acted as a wonderful steward to our business, fostering both its growth and success," Peek said in a news release. "As MI enters a new era of product development, innovation and commercialization, we felt it was the right time to strike out on our own."

Customer Referrals

ASDx Biosystems

ASDx Biosystems specializes in the development of immunoassays for environmental agents, foodborne pathogens, infectious diseases and oncology biomarkers using luminescence detection technologies. The company and its team of international experts provide customers with the most advanced antibody, detection reagent and instrument technologies available.

In its evaluation of potential OEM partners to manufacture arrays, Dr. Peter Andreotti, CEO of ASDx Biosystems, searched for an experienced microarray vendor that could not only deliver high quality arrays but also work as a development partner with ASDx to accelerate the development process. After looking into several vendors, Dr. Andreotti selected MI.

"One major thing that helped MI stand out from other vendors was the company's ability to customize its service to address the unique and specific needs of customers," mentioned Dr. Andreotti. "For example, MI was able to produce and modify test plates that allowed us to go through several developmental cycles, a process we found very useful. Thanks to MI, we are now able to shorten the time needed to develop assays for our clients."

In January 2010, ASDx Biosystems established a collaboration with MI for the development of a multiplexed luminescent immunoassay detection platform. The resulting luminescent immunoassays and multiplexed immunoassay systems have widespread applications in research and diagnostics, including in proteomics and genomics, as well as in toxin, microbial, infectious disease, autoimmune disease and oncology detection.

Today, with MI as a partner, ASDx Biosystems' industry-leading luminescence immunoassays are at the forefront of advancing the development, testing and deployment of critical biothreat, infectious agent and oncology biomolecular detection systems.

Immuno Concepts

Founded in 1979 with a commitment to advance the quality of diagnostic assays for systemic rheumatic diseases, Immuno Concepts pioneered the conversion from rodent tissue to HEp-2 cells for detection of anti-nuclear antibodies (ANAs). This product, HEp-2000 coupled with their colorzyme methodology, offers increased sensitivity for detection of autoantibodies to SS-A/Ro. The company is certified to ISO 9001 and actively pursuing CE mark certification for its products.

In 2005, Immuno Concepts set out to develop an entirely new approach for testing for autoimmune diseases, including lupus, AIDS and scleroderma. The concept was to build an array that could test for 10 antibodies linked to autoimmune diseases, make the test easy to run and ensure that the results were easy to read and cost-accessible for organizations of all sizes.

Immuno Concepts searched the country for a company to produce the arrays, but couldn't find a partner that seemed to fit. With several potential vendors, Immuno Concepts felt that there was little relationship building and no collaboration, two factors that the company believed were critical for a successful, long-term relationship. Finally, Jack Horner, CEO, turned to the Web and found MI.

In the first few years of working together, there were multiple occasions when Jack and his team felt like they may have bit off more than they could chew, but the personal relationship the company had built with MI helped Immuno Concepts continue to move forward.

"We wouldn't be where we are today without Microarrays Inc and I firmly believe that we would have wasted a lot of time and money trying to achieve our goal if we hadn't partnered with MI early on," said Jack Horner. "MI's quality control is unsurpassed, giving us peace of mind that the tests we deliver to customers will yield high quality, reproducible results."

Today, the array developed by Immuno Concepts and produced by MI has the ability to test for 10 different antibodies linked to a variety of autoimmune diseases using a single sample, giving doctors critical information about their patients in less time and with less testing than ever before. Immuno Concepts is expecting CE-marking for its technology in January 2011 and will then submit for FDA review.

Ocean Ridge Biosciences

Ocean Ridge Biosciences (ORB) is a growing life science company developing new tools for expression profiling focused on screening of low abundance non-coding and non-polyadenylated mRNAs. ORB specializes in providing customized results from difficult-to-work-with samples for academic and biotechnology customers.

Recently, ORB collaborated with the Scripps Research Institute in Florida to validate and apply ORB products and services for research on neurological disorders. When ORB began looking for a partner to produce custom arrays in 2006, the company tested products from several vendors; they found that no other company provided the quality, dependability and reproducibility offered by MI.

Having used and evaluated gene expression arrays from better-known commercial vendors, ORB recommends and uses MI ReadyArrays for human and mouse. Working with the MI ReadyArrays has become a key component of ORB's customized method for processing arrays and has helped ensure that ORB delivers results for their clients with unparalleled sensitivity, specificity and reproducibility. The quality of those experimental results has made the MI ReadyArray for mouse a critical component of several clinical studies published in the Journal of Clinical Investigation).

"We firmly believe that Microarrays' platform has made it possible for us to deliver results that achieve a level of precision, sensitivity and reproducibility unavailable anywhere else in the industry," said Dr. David A. Willoughby of Ocean Ridge Biosciences. "The company is a true partner in every sense of the word, working closely with us to quickly and accurately fine tune every array to meet the special requirements of our research and clinical customers."

Radiation Oncology - Rush University Medical Center

Rush University Medical Center is a 676 bed not-for-profit health care, education and research enterprise, and home to one of the first medical colleges in the Midwest. Graduate programs in allied health, health systems management and biomedical research are offered. Dr. Victor Levenson, an associate professor at the Medical Center, and his team of scientists have focused their research on DNA methylation as a blood-based biomarker for early diagnosis, prognosis and prediction of drug effects in oncology and Multiple Sclerosis.

During his search to establish a variety of biomarkers for testing multiple elements in each clinical sample, Dr. Levenson and his team designed a proof-of-principal microarray probe. They sought advice from experts on how well they had designed their probes hoping that the evaluation and proof-of principle process would help them identify a vendor capable of providing early project development to large scale manufacturing services. After evaluating upwards of seven providers, Dr. Levenson and his team concluded that MI was the right partner.

"When dealing with a business partner, we look for them to take responsibility for the product from start to finish," commented Dr. Levenson. "MI was great in that respect. Not only do they continue to provide consistent and quality outcomes, but they also offer personal customer service. For example, MI went to great lengths to adjust the concentration of the DNA printed on our arrays in order to ensure that the final product was as good as could be."

Today, MI continues to print the microarrays that Dr. Levenson and his team use for their groundbreaking studies. In addition, MI's industry expertise has helped Rush cut costs involved in carrying out their cutting-edge research.